Apyx Medical Gains FDA Clearance for AYON System

The latest announcement is out from Apyx Medical ( (APYX) ).

On May 13, 2025, Apyx Medical Corporation announced it received FDA clearance for its AYON Body Contouring System, a pioneering all-in-one platform for aesthetic surgery. The system integrates multiple technologies to enhance surgical precision and patient outcomes, and its commercial launch is planned for the second half of 2025. This development positions Apyx Medical at the forefront of the growing body contouring market, driven by an increase in demand from patients experiencing rapid weight loss.

The most recent analyst rating on (APYX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Apyx Medical stock, see the APYX Stock Forecast page.

Spark’s Take on APYX Stock

According to Spark, TipRanks’ AI Analyst, APYX is a Neutral.

Apyx Medical’s overall stock score reflects significant financial and valuation challenges, offset by some positive momentum in technical indicators and strategic improvements discussed in the earnings call. Persistent profitability issues and a negative P/E ratio weigh heavily on the score, while potential growth from new product launches offers some optimism.

To see Spark’s full report on APYX stock, click here.

More about Apyx Medical

Apyx Medical Corporation is an advanced energy technology company specializing in innovative products for cosmetic and hospital surgical markets. Its offerings include the Helium Plasma Platform Technology, marketed as Renuvion and J-Plasma, which provide controlled heat to tissue for desired surgical outcomes. The company leverages its expertise through OEM agreements with other medical device manufacturers.

Average Trading Volume: 52,678

Technical Sentiment Signal: Strong Sell

Current Market Cap: $41.76M

See more insights into APYX stock on TipRanks’ Stock Analysis page.